UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial

McEwan, Phil; Davis, Jason A; Gabb, Peter D; Wheeler, David C; Rossing, Peter; Chertow, Glenn M; Correa-Rotter, Ricardo; ... Garcia Sanchez, Juan Jose; + view all (2024) Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial. Clinical Kidney Journal , 17 (2) , Article sfae025. 10.1093/ckj/sfae025. Green open access

[thumbnail of Wheeler_Dapagliflozin in chronic kidney disease_VoR.pdf]
Preview
Text
Wheeler_Dapagliflozin in chronic kidney disease_VoR.pdf - Published Version

Download (1MB) | Preview

Abstract

Background: The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial enrolled patients with estimated glomerular filtration rate 25–75 mL/min/1.73 m2 and urine albumin-to-creatinine ratio >200 mg/g. The Dapagliflozin Effect on CardiovascuLAR Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial enrolled patients with type 2 diabetes, a higher range of kidney function and no albuminuria criterion. The study objective was to estimate the cost-effectiveness of dapagliflozin in a broad chronic kidney disease population based on these two trials in the UK, Spain, Italy and Japan. // Methods: We adapted a published Markov model based on the DAPA-CKD trial but to a broader population, irrespective of urine albumin-to-creatinine ratio, using patient-level data from the DAPA-CKD and DECLARE-TIMI 58 trials. We sourced cost and utility inputs from literature and the DAPA-CKD trial. The analysis considered healthcare system perspectives over a lifetime horizon. // Results: Treatment with dapagliflozin was predicted to attenuate disease progression and extend projected life expectancy by 0.64 years (12.5 versus 11.9 years, undiscounted) in the UK, with similar estimates in other settings. Clinical benefits translated to mean quality-adjusted life year (QALY; discounted) gains between 0.45 and 0.68 years across countries. Incremental cost-effectiveness ratios in the UK, Spain, Italy and Japan ($10 676/QALY, $14 479/QALY, $7771/QALY and $13 723/QALY, respectively) were cost-effective at country-specific willingness-to-pay thresholds. Subgroup analyses suggest dapagliflozin is cost-effective irrespective of urinary albumin-to-creatine ratio and type 2 diabetes status. // Conclusion: Treatment with dapagliflozin may be cost-effective for patients across a wider spectrum of estimated glomerular filtration rates and albuminuria than previously demonstrated, with or without type 2 diabetes, in the UK, Spanish, Italian and Japanese healthcare systems.

Type: Article
Title: Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/ckj/sfae025
Publisher version: http://dx.doi.org/10.1093/ckj/sfae025
Language: English
Additional information: Copyright © The Author(s) 2024. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Albuminuria, chronic kidney disease, cost-effectiveness, dapagliflozin, SGLT2 inhibitor
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10188160
Downloads since deposit
11Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item